Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX11 in Obesity or Overweight
NCT07652047Phase 1Recruiting
- Sponsor
- CORXEL Pharmaceuticals
- Start
- May 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VCT220 in obesity (4 arms), sponsored by CORXEL Pharmaceuticals. Primary endpoint: Percentage change in body weight from baseline at 26 weeks. Started May 2026; status: recruiting.
02
Drugs
VCT220
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07652047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652047.